The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Final results from ClarIDHy
Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, discusses the final results from ClarIDHy (NCT02989857), a Phase III randomized study of ivosidenib versus placebo in patients with previously treated IDH1-mutated cholangiocarcinoma (CCA). Ivosidenib was found to be well-tolerated and resulted in a favorable overall survival when compared to placebo, demonstrating clinical benefit of ivosidenib in advanced IDH1-mutated CCA. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
